Chemoresistance of human monocyte-derived dendritic cells is regulated by IL-17A.

Abstract

Dendritic cells initiate adaptive immune responses, leading either to control cancer by effector T cells or to exacerbate cancer by regulatory T cells that inhibit IFN-γ-mediated Th1-type response. Dendritic cells can also induce Th17-type immunity, mediated by IL-17A. However, the controversial role of this cytokine in cancer requires further investigations. We generated dendritic cells from peripheral blood monocytes to investigate lifespan, phenotype and chemoresistance of dendritic cells, treated with IL-17A with or without IFN-γ. Studying the expression of Bcl-2 family members, we demonstrated that dendritic cells constitutively express one pro-survival Bcl-2 member: MCL1. Immature dendritic cells were CD40(low)HLADR(low) CD1a(+) MCL1(+), did not express CD14, CD68 or BCL2A1, and displayed a short 2-day lifespan. IL-17A-treated DC exhibited a semi-mature (CD40(high) HLADR(low)) pre-M2 (CCL22(+) CD206(+) CD163(+) IL1RN(+) IL-10(-) CXCL10(-) IL-12(-)) mixed (CD1a(+) CD14+ CD68(+)) macrophage-dendritic cell phenotype. They efficiently exerted mannose receptor-mediated endocytosis and did not produce superoxide anions, in the absence of TLR engagement. Interestingly, IL-17A promoted a long-term survival of dendritic cells, beyond 12 days, that correlated to BCL2A1 induction, a pro-survival Bcl-2 family member. BCL2A1 transcription was activated by NF-κB, downstream of IL-17A transduction. Thus, immature dendritic cells only express MCL1, whereas IL-17A-treated dendritic cells concomitantly expressed two pro-survival Bcl-2 family members: MCL1 and BCL2A1. These latter developed chemoresistance to 11 of the 17 chemotherapy agents tested. However, high doses of either vinblastine or cytarabine decreased MCL1 expression and induced dendritic cell death. When IL-17A is produced in vivo, administration of anti-IL-17A biotherapy may impair dendritic cell survival by targeting BCL2A1 expression. Consequently, depending on the effector or regulatory role of dendritic cells, blocking IL-17A, may be either dangerous or beneficial for cancer outcomes, thus contributing to the apparent controversy around the role of IL-17A in cancer.

• Authors: Selma Olsson Åkefeldt, Carine Maisse, Alexandre Belot, Marlène Mazzorana, Giulia Salvatore, Nathalie Bissay, Pierre Jurdic, Maurizio Aricò, Chantal Rabourdin-Combe, Jan-Inge Henter, Christine Delprat
• Journal: PloS one (PLoS One) Vol. 8 Issue 2 Pg. e56865 ( 2013) ISSN: 1932-6203 [Electronic] United States
• PMID: 23441221 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• BCL2-related protein A1
• Interleukin-17
• Minor Histocompatibility Antigens
• Myeloid Cell Leukemia Sequence 1 Protein
• NF-kappa B
• Proto-Oncogene Proteins c-bcl-2
• Interferon-gamma

Topics

• Antineoplastic Agents (pharmacology)
• Cell Differentiation
• Cell Proliferation (drug effects)
• Cell Survival (drug effects)
• Cells, Cultured
• Dendritic Cells (cytology, drug effects, metabolism)
• Drug Resistance, Neoplasm (genetics)
• Gene Expression Regulation (drug effects)
• Humans
• Immunophenotyping
• Interferon-gamma (pharmacology)
• Interleukin-17 (pharmacology)
• Minor Histocompatibility Antigens
• Monocytes (cytology)
• Myeloid Cell Leukemia Sequence 1 Protein
• NF-kappa B (metabolism)
• Phenotype
• Protein Transport (drug effects)
• Proto-Oncogene Proteins c-bcl-2 (genetics, metabolism)
• Transcription, Genetic